SCHEDULE 13G/A: Vanguard Group Discloses 7.9% Passive Stake in Sage Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting a 7.9% passive ownership stake in Sage Therapeutics Inc. as of December 31, 2024.

Summary

• The Vanguard Group filed an Amendment No. 11 to Schedule 13G concerning its beneficial ownership in Sage Therapeutics Inc.
• As of December 31, 2024, The Vanguard Group beneficially owned an aggregate of 4,838,169 shares of Sage Therapeutics Inc. common stock.
• This ownership represents 7.9% of the class of securities.
• The Vanguard Group holds sole dispositive power over 4,754,257 shares and shared dispositive power over 83,912 shares.
• The firm holds shared voting power over 37,104 shares and no sole voting power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing passive ownership by a large institutional investor. It contains no information that would inherently suggest positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• A major institutional investor, The Vanguard Group, maintains a significant 7.9% stake in Sage Therapeutics Inc., indicating its inclusion in various Vanguard funds and portfolios.

Risks

• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer, mitigating concerns about potential activist investor actions.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Ashley Grim, Head of Global Fund Administration, The Vanguard Group)

Industry Context

This filing reflects a routine disclosure by a major asset manager, The Vanguard Group, regarding its passive investment holdings in a publicly traded biotechnology company, Sage Therapeutics Inc. Such filings are common for large institutional investors whose holdings exceed 5% of a company's outstanding shares, indicating their inclusion in various index or actively managed funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive institutional holding by The Vanguard Group, which may offer some reassurance regarding institutional interest in the company.

Key Dates

Keywords

Sage Therapeutics, Vanguard Group, Schedule 13G, Institutional Ownership, SEC Filing, Common Stock, Investment Adviser